Nintx and CIEnP will collaborate on the research of medicinal plants to develop novel therapies for chronic multifactorial inflammatory bowel diseases (multi-target therapies)
We are excited to announce the partnership between Nintx and Centro de Inovação e Ensaios Pré-Clínicos (CIEnP) to develop multi-target therapies against inflammatory bowel diseases. Nintx and CIEnP will map, select, and experiment on medicinal plants to develop multi-target therapies against Crohn's disease and ulcerative colitis. “CIEnP researchers, since the 1990s, have been closely working in partnership with the main Brazilian pharma and cosmetics companies in the preclinical development of projects aimed at obtaining plant-based pharmaceutical products and anti-aging ingredients. Nintx, with its know-how in discovery and development (preclinical, API/Formulation, clinical, and business), will perfectly complement our Preclinical Platform”, said Dr. João B. Calixto, President Director of CIEnP. “CIEnP has deep knowledge and experience in partnering with industries to transform medicinal plants into high-quality preclinical candidates. The idea is to couple this with our proprietary technologies in the human microbiome field (xGIbiomics®) to develop therapies that modulate human biological targets and the microbiome concomitantly (multi-target therapies), aiming at the treatment of chronic multifactorial inflammatory bowel diseases”, stated Dr. Cristiano R. W. Guimaraes, CSO, Nintx.
To have access to the full content, check us out on LinkedIn.
Comments